Jaka jest cena za Arno Therapeutics, Inc. (ARNI)

Cena za Arno Therapeutics, Inc. (ARNI) wynosi $0.0001

Jaka jest kapitalizacja rynkowa dla Arno Therapeutics, Inc. (ARNI)

Kapitalizacja rynkowa dla Arno Therapeutics, Inc. (ARNI) wynosi $4.94K

Przychody Arno Therapeutics, Inc. (ARNI)

Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.

Rok	Przychody	Zmień
Za mało danych dla podanych dat.

Rok

Przychody

Zmień

Za mało danych dla podanych dat.

Firma	Przychody	Różnica w przychodach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Firma

Przychody

Różnica w przychodach

Kraj